Understanding the mechanisms involved in pathway choice for DSB repair is crucial to develop targeted therapeutic interventions in cancer cells, as, for example, is the case of poly-ADP ribose polymerase (PARP) inhibitors in Brca1-deficient cancers [6]. The gene discussed is PARP1; the disease is cancer.